Group 1 - The company announced the conditional redemption of its convertible bonds, "Jianyou Convertible Bonds," allowing bondholders to sell their bonds back to the company at a price of 100.30 RMB per bond, including accrued interest [2][10][11] - The redemption period is set from June 17, 2025, to June 23, 2025, with funds to be disbursed on June 26, 2025 [3][11] - The bonds will stop converting into shares during the redemption period, but trading will continue [3][13] Group 2 - The company’s subsidiary, Meitheal Pharmaceuticals, received FDA approval for the production site transfer of Daunorubicin Hydrochloride Injection, which is used in the treatment of acute non-lymphocytic leukemia and acute lymphoblastic leukemia [15][16] - The approved product is expected to be launched in the U.S. market soon, which may positively impact the company's financial performance [18]

Core Points - The company announced the option for bondholders to sell back the "Jianyou Convertible Bonds" at a price of 100.30 RMB per bond, including accrued interest and tax [1][4] - The sell-back period is set from June 17, 2025, to June 23, 2025, with funds to be disbursed on June 26, 2025 [1][4] - During the sell-back period, the "Jianyou Convertible Bonds" will stop being convertible into shares [1][4] Summary of Key Details Sell-Back Terms - The sell-back price is determined based on the face value plus accrued interest, calculated as approximately 0.30 RMB per bond for the period from April 23, 2025, to June 17, 2025 [3][4] - The bondholders have the right to sell back all or part of their unconverted bonds, but this action is not mandatory [4][5] Conditions for Sell-Back - The sell-back option is activated if the company's stock price remains below 70% of the current conversion price for any consecutive thirty trading days during the last two interest years of the bonds [2][3] - If bondholders do not exercise their sell-back rights during the specified period, they will lose the option for the current interest year [2][3] Trading and Suspension - The "Jianyou Convertible Bonds" will continue to trade during the sell-back period but will not be convertible into shares [4][5] - If the total face value of the bonds in circulation falls below 30 million RMB due to the sell-back, trading will continue until the end of the sell-back period, after which the company will issue a related announcement [5]

证券代码：603707 证券简称：健友股份 公告编号：2025-046 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 关于"健友转债"可选择回售的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、回售条款及回售价格 （一）回售条款 根据"健友转债"《募集说明书》的约定，有条件回售条款为：在本次可转债 最后两个计息年度内，如果公司股票收盘价在任何连续三十个交易日低于当期转 股价格的 70%时，本次可转债持有人有权将其持有的本次可转债全部或部分以面 值加上当期应计利息回售给公司。若在上述交易日内发生过转股价格因发生派送 股票股利、转增股本、增发新股（不包括因本次发行的可转债转股而增加的股本）、 配股以及派发现金股利等情况而调整的情形，则在调整日前的交易日按调整前的 转股价格和收盘价格计算，在调整日及之后的交易日按调整后的转股价格和收盘 价格计算。如果出现转股价格向下修正的情况，则上述"连续三十个交易日"须 从转股价格调整之后的第一个交易日起按修正后的转股价格重新计算。 当期应计利息的计算公式为： ...

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-047 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | （二）适 应 症：与其他抗癌药物联合使用，适用于成人急性非淋巴细胞白 血病（包括粒细胞性白血病、单核细胞白血病及红白血病）的治疗，以及儿童和 成人急性淋巴细胞白血病的治疗。 （三）剂 型：注射剂 南京健友生化制药股份有限公司 子公司关于获得美国 FDA 盐酸柔红霉素注射液 药品生产场地转移注册批件的公告 二、药品其他相关情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司于 2025 年 6 月 9 日收到美国 FDA 的通知，公司子公司 Meitheal 向美国 FDA 申报的盐酸柔红霉素注射液，20 mg/4 mL（ANDA 号：065035）生产场地 转移至健进制药有限公司的申请已获得批准。 南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）子公司 Meitheal Pharmaceuticals, Inc.（以 ...

债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | | 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，应于每个月的前 3 个交易日内 披露截至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 截至 2025 年 5 月 31 日，公司尚未实施股份回购。 三、其他事项 重要内容提示： | 回购方案首次披露日 | 2025/4/29，由董事长唐咏群先生提议 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 2025 5 | 5 | 月 | 20 | 日~2026 | 年 | 月 | 日 19 | | 预计回购金额 | 2,000万元~4,000万元 | | | | | | | | | 回购用途 | □减少注册资 ...

证券代码：603707 证券简称：健友股份 公告编号：2025-045 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）子公司健 进制药有限公司（以下简称"健进制药"）于近日收到美国食品药品监督管理局 （以下简称"美国 FDA"）签发的盐酸肼屈嗪注射液，20 mg/mL，单剂量的 ANDA 批准通知（ANDA 号：217501）。现将相关情况公告如下： 一、药品的基本情况 （一）药品名称：盐酸肼屈嗪注射液 （二）适 应 症：适用于严重原发性高血压患者在无法口服给药或需紧急降 压的情况下使用 （三）剂 型：注射剂 二、药品其他相关情况 公司于 2025 年 06 月 04 日收到美国 FDA 的通知，公司子公司健进制药向美 国 FDA 申报的盐酸肼屈嗪注射液，20 mg/mL 的 ANDA 申请获得批准。 南京健友生化制药股份有限公司 关于子公司产品盐酸肼屈嗪注射液获得美国 FDA 批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 经查询，美国境内，目前另 ...

Core Points - The company announced a cash dividend distribution of 0.1 yuan per share for the fiscal year 2024, totaling approximately 161.56 million yuan [2][4] - The dividend distribution plan was approved at the company's annual general meeting on May 20, 2025 [2][6] - The cash dividends will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [3] Dividend Distribution Details - The total share capital before the distribution is 1,615,634,969 shares, with a cash dividend of 0.1 yuan per share [4] - Shareholders who have completed designated trading can receive their cash dividends on the distribution date at their designated securities firms [5] - For shareholders holding unrestricted circulating shares, the cash dividend will be distributed through the clearing system of the China Securities Depository and Clearing Corporation [5] Taxation Information - For individual shareholders holding unrestricted circulating shares for more than one year, the cash dividend is exempt from personal income tax, resulting in an actual distribution of 0.1 yuan per share [8] - For shares held for one year or less, the company will not withhold personal income tax at the time of distribution, but tax will be calculated based on the holding period when the shares are sold [8] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.09 yuan per share [10] Convertible Bond Adjustment - The company announced an adjustment to the conversion price of its convertible bonds, "Jianyou Convertible Bonds," effective June 5, 2025, changing from 24.44 yuan to 24.34 yuan per share [14][16] - The adjustment is based on the company's 2024 annual profit distribution plan, which includes a cash dividend distribution [15][16] - The conversion of the bonds will be suspended from May 28 to June 4, 2025, and will resume on June 5, 2025 [16]

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-043 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于"健友转债"转股价格调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次"健友转债"转股价格调整实施日期：2025 年 6 月 5 日 经中国证券监督管理委员会证监许可[2020]134 号文核准，南京健友生化制药 股份有限公司（以下简称"公司"）于 2020 年 4 月 23 日公开发行了 5,031,900 张可转换公司债券，每张面值 100 元，发行总额 50,319 万元，并于 2020 年 5 月 22 日起在上海证券交易所挂牌交易，债券简称"健友转债"，债券代码 113579。 健友转债存续期 6 年，自 2020 年 4 月 23 日至 2026 年 4 月 22 日，转股起止日期 自 2020 年 10 月 29 日至 2026 年 4 月 22 日，初始转股价格 ...

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-042 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.1元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/4 | － | 2025/6/5 | 2025/6/5 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 20 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利 ...

Group 1 - Company Sun Energy plans to repurchase shares worth between 100 million to 200 million yuan for cancellation, with a maximum repurchase price of 6.69 yuan per share [1] - Company Runyang Technology intends to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., with a pre-investment valuation of 8 billion yuan [1] - Company Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4712 injection for treating advanced solid tumors [2] Group 2 - Company Lianhuan Pharmaceutical plans to increase capital by 60 million yuan for its wholly-owned subsidiary [2] - Company Hongchang Electronics' subsidiary plans to increase capital by 10 million USD for its other subsidiary [2] - Company Sichuan Meifeng intends to repurchase shares worth between 50 million to 70 million yuan for cancellation, with a maximum repurchase price of 10.07 yuan per share [2] Group 3 - Company Lian Micro plans to liquidate and deregister Jiaxing Kangjing Semiconductor Industry Investment Partnership [4] - Company Jiutian Pharmaceutical has received approval for clinical trials of PDX-04 drug for treating acute gout attacks [5] - Company Pingzhi Information has signed a framework agreement with China Telecom for a GPU computing power project worth approximately 246 million yuan [7] Group 4 - Company Jiu Zhi Tang's subsidiary has initiated Phase II clinical trials for new drug YB211 aimed at treating acute bacterial skin infections [8] - Company Fosun Pharma's subsidiary has received orphan drug designation for HLX22 for gastric cancer treatment in the EU [9] - Company Jianyou Co. plans to repurchase shares worth between 20 million to 40 million yuan for employee stock ownership plans [11] Group 5 - Company Zhi Zheng Co. announced the resignation of its vice president due to personal reasons [13] - Company He Mai Co. signed a cooperation agreement for household photovoltaic systems worth 1 billion yuan [14] - Company Jinan Intelligent's subsidiary won a project bid for electric vehicle charging stations, expected to positively impact performance [16] Group 6 - Company Gaotie Electric plans to distribute a cash dividend of 0.012 yuan per share [18] - Company Guyue Longshan plans to distribute a cash dividend of 0.08 yuan per share [18] - Company Yongmaotai's shareholders plan to reduce their holdings by up to 2.66% of the company's shares [19] Group 7 - Company Tian Cheng Technology's subsidiary received a land idle fee notice for 2.1658 million yuan due to project delays [20] - Company Guangri Co. appointed a new vice president and board secretary to enhance governance [21] - Company Design General Institute won multiple major projects totaling approximately 390 million yuan [22] Group 8 - Company Fuxie Environmental signed a significant contract worth 244 million yuan for a sewage treatment project [23] - Company Lujiazui announced the resignation of its vice chairman due to job transfer [24] - Company Three Squirrels' H-share issuance application has been accepted by the CSRC [24] Group 9 - Company Kanghong Pharmaceutical's subsidiary received approval for clinical trials of KH617 for glioblastoma treatment [25] - Company Xin Zhu Co. announced a suspension of trading to plan an asset acquisition from its controlling shareholder [26] - Company Jianxin Co. announced plans for share reductions by several directors and senior management [28]